Repinatrabit
Phenylketonuria (PKU)
About Otsuka
Otsuka America Pharmaceutical, Inc. is the U.S. pharmaceutical arm of Japan's Otsuka Holdings, operating as a commercial-stage biopharmaceutical company. It has a long-standing legacy in neuroscience with marketed products and is actively expanding its pipeline in nephrology, immunology, and CNS disorders through internal R&D and strategic acquisitions like Transcend Therapeutics. The company is led by a seasoned executive team and leverages the global resources of its parent organization to address significant unmet medical needs.
View full company profileAbout Otsuka
Otsuka America Pharmaceutical, Inc. is the U.S. pharmaceutical arm of Japan's Otsuka Holdings, operating as a commercial-stage biopharmaceutical company. It has a long-standing legacy in neuroscience with marketed products and is actively expanding its pipeline in nephrology, immunology, and CNS disorders through internal R&D and strategic acquisitions like Transcend Therapeutics. The company is led by a seasoned executive team and leverages the global resources of its parent organization to address significant unmet medical needs.
View full company profileTherapeutic Areas
Other Phenylketonuria (PKU) Drugs
| Drug | Company | Phase |
|---|---|---|
| SYNB1934 | Synlogic | Phase 3 |
| PKU Treatment | Cycle Pharmaceuticals | Commercial |
| NB-20X | Nerai Biosciences | Pre-clinical |
| NGGT002 | NGGT | Phase 1/2 (inferred) |
| SOM1311 | SOM Biotech | Preclinical |
| PER303 | Perseo Pharma | Preclinical |
| Engineered Native Bacteria Platform | Endure Biotherapeutics | Pre-clinical |
| JNT-517 | JCR Pharmaceuticals | Phase 1 |
| PALYNZIQ (pegvaliase-pqpz) | BioMarin Pharmaceutical | Approved/Marketed |
| PTC923 (sepiapterin) | PTC Therapeutics | Phase 3 |